Last reviewed · How we verify

recombinant human erythropoietin, rhEpo

Claudia Sue Robertson · Phase 2 active Small molecule

recombinant human erythropoietin, rhEpo is a Small molecule drug developed by Claudia Sue Robertson. It is currently in Phase 2 development.

At a glance

Generic namerecombinant human erythropoietin, rhEpo
SponsorClaudia Sue Robertson
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about recombinant human erythropoietin, rhEpo

What is recombinant human erythropoietin, rhEpo?

recombinant human erythropoietin, rhEpo is a Small molecule drug developed by Claudia Sue Robertson.

Who makes recombinant human erythropoietin, rhEpo?

recombinant human erythropoietin, rhEpo is developed by Claudia Sue Robertson (see full Claudia Sue Robertson pipeline at /company/claudia-sue-robertson).

What development phase is recombinant human erythropoietin, rhEpo in?

recombinant human erythropoietin, rhEpo is in Phase 2.

Related